JAMP ITRACONAZOLE ORAL SOLUTION

Maa: Kanada

Kieli: englanti

Lähde: Health Canada

Aktiivinen ainesosa:

ITRACONAZOLE

Saatavilla:

JAMP PHARMA CORPORATION

ATC-koodi:

J02AC02

INN (Kansainvälinen yleisnimi):

ITRACONAZOLE

Annos:

10MG

Lääkemuoto:

SOLUTION

Koostumus:

ITRACONAZOLE 10MG

Antoreitti:

ORAL

Kpl paketissa:

15G/50G

Prescription tyyppi:

Prescription

Terapeuttinen alue:

AZOLES

Tuoteyhteenveto:

Active ingredient group (AIG) number: 0123311001; AHFS:

Valtuutuksen tilan:

APPROVED

Valtuutus päivämäärä:

2018-12-31

Valmisteyhteenveto

_JAMP Itraconazole Oral Solution (Itraconazole Oral Solution) _
_ _Page 1 of 63
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
JAMP ITRACONAZOLE ORAL SOLUTION
Itraconazole oral solution
solution, 10 mg/mL, oral
Antimycotic for systemic use, triazole and tetrazole derivatives.
JAMP Pharma Corporation
1310 rue Nobel
Boucherville, Quebec
J4B 5H3, Canada
Date of Initial Authorization:
December 31, 2018
Date of Revision:
February 2, 2024
Control Number: 278552
_JAMP Itraconazole Oral Solution (Itraconazole Oral Solution) _
_ _Page 2 of 63
RECENT MAJOR LABEL CHANGES
2 CONTRAINDICATIONS
02/2024
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
RECENT MAJOR LABEL CHANGES ................................................................................................................................................
2
TABLE OF CONTENTS
.............................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
.....................................................................
4
1
INDICATIONS
..............................................................................................................
4
1.1
Pediatrics
........................................................................................................
4
1.2
Geriatrics
........................................................................................................
4
2
CONTRAINDICATIONS
.................................................................................................
4
3
SERIOUS WARNINGS AND PRECAUTIONS BOX
........................................................... 6
4
DOSAGE AND ADMINISTRATION
................................................................................
6
4.1
Dosing Considerations
....................................................................................
6
4.2
Recommended Dose and Dosage Adjustment
............................................... 7
4.